Sanaria Inc.: Malaria, Falciparum trials

The registry lists 12 Malaria, Falciparum studies with Sanaria Inc. as lead sponsor. 4 are open to participants now and 3 have results posted.

Phase 1 8Phase 2 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina FasoNot yet recruitingNCT07730177Phase 1
• PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in MaliRecruitingNCT07675785Phase 2
• Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe AdultsRecruitingNCT07385287Phase 2
• Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve AdultsRecruitingNCT06862453Phase 1
• A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMITerminatedNCT05604521Phase 1Results posted
• PfSPZ Vaccine Trial in Malian ChildrenCompletedNCT04940130Phase 2Results posted
• Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted MalariaCompletedNCT03503058Phase 2Results posted
• Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina FasoCompletedNCT06652737Phase 1
• Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian AdultsCompletedNCT03420053Phase 1
• Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ ChallengeCompletedNCT02237586Phase 1
• Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian AdultsCompletedNCT02132299Phase 1
• Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under ChemoprophylaxisCompletedNCT02115516Phase 1